Please assess the completion status of the following clinical trial:

Trial Title: Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Inclusion criteria is pragmatic and informed by Canadian Best Practices.~* All patients with acute ischemic stroke eligible to receive intravenous alteplase as per standard care will be eligible for enrolment in the proposed trial.~* Patients eligible for endovascular thrombectomy in addition to intravenous thrombolysis are eligible for enrolment.~Exclusion Criteria:~* Contra-indications to intravenous thrombolysis as used by treating physicians as current standard of care apply.~* The benefits of thrombolysis with intravenous alteplase in the pediatric population is unknown. Any patient \< 18 years of age may therefore not be enrolled.~* Women with pregnancy known to the investigator by history or examination, without requiring pregnancy testing, may only be enrolled in consultation with an expert stroke physician (either in person or through tele-stroke)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tenecteplase (tNK-TPA) (Type: ACTIVE_COMPARATOR): The intervention group will receive intravenous tenecteplase as a single bolus as per the standard manufacturers' instructions for use. The dose administered will be 0.25 mg/kg body weight (maximum dose 25 mg) over 10-20 seconds as soon as possible after randomization. Tenecteplase has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
- Alteplase ( tPA) (Type: ACTIVE_COMPARATOR): The control group will receive standard of care dosing of intravenous alteplase (0.9 mg/kg body weight, 10% bolus and 90% infusion as per standard care, maximum dose 90 mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).